# Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

> **NCT07147426** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Head &Amp; Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab Combined With Chemotherapy for 4 cycles
- **DRUG:** Tislelizumab Combined With Chemotherapy for 2 cycles

## Key facts

- **NCT ID:** NCT07147426
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-20
- **Primary completion:** 2026-10-20
- **Final completion:** 2028-10-20
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07147426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07147426, "Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07147426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*